Abstracts tagged "Enthesitis"

Abstract Number: 1340 • ACR Convergence 2021
Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
Fabrizio Cantini¹, Antonio Marchesoni², Francesca Marando³, Giuliana Gualberti³, Lucia Novelli³, Giacomo Curradi³, Erin McDearmon-Blondell⁴, Tianming Gao⁵ and Carlo Salvarani⁶, ¹Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy, ²Dipartimento di Reumatologia, ASST Gaetano Pini-CTO, Milano, Italy, ³AbbVie, Rome, Italy, ⁴AbbVie Inc., Elmhurst, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and…
Abstract Number: 1797 • ACR Convergence 2021
Are Smoking and Alcohol Associated with Peripheral Musculoskeletal Involvement in Patients with Spondyloarthritis? Results from the ASAS-PerSpA Study
M.Lourdes Ladehesa-Pineda¹, Rafaela Ortega², Mara ngeles Puche Larrubia¹, Maxime Dougados³, Eduardo Collantes-Estevez² and Clementina López Medina⁴, ¹Hospital Universitario Reina Sofía, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: There are controversies around the role of smoking in manifestations of axial spondyloarthritis (axSpA) such as peripheral involvement. It has been observed an inverse…
Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Rita Torres¹, Santiago Manica² and Fernando Santos², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…
Abstract Number: 0149 • ACR Convergence 2021
Development of Joint Effusion, Hyperperfusion and Enthesitis After One Hour of Age-and Gender Adjusted Weight Training
Julia Schreiner¹, Dennis Scheicht², Pantelis Karakostas³, Jana Ziob¹, Charlotte Behning¹, Peter Preuss⁴, Peter Brossart⁵ and Valentin Schäfer¹, ¹University Hospital Bonn, Bonn, Germany, ²Porz am Rhein Hospital, Cologne, Germany, ³Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ⁴University of Bonn, Bonn, Germany, ⁵Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
Background/Purpose: Ultrasound is an established tool to detect changes of joints, tendons and entheses in rheumatology. However, several studies detected structural and vascular changes in…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 287 • 2019 ACR/ARP Annual Meeting
Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review
Nancy Desai¹, Justin Bucci ¹ and Eugene Kissin ², ¹Boston Medical Center, Boston, ²Boston University, Boston, MA
Background/Purpose: Ultrasound (US) evaluation of the Achilles tendon has been utilized to assess involvement at the entheses in the setting various inflammatory, metabolic and mechanical…
Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
Abstract Number: 1493 • 2019 ACR/ARP Annual Meeting
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Joseph Merola¹, Aubrey Trevelin Sprabery ², Amanda Gellett ², Chen-Yen Lin ² and Dennis McGonagle ³, ¹Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²Eli Lilly and Company, Indianapolis, IN, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Multiple biologic DMARD (bDMARD) treatments are available for PsA, but there is limited research that compares the safety and efficacy of these treatments. Head-to-head…
Abstract Number: 1778 • 2019 ACR/ARP Annual Meeting
Entheseal CD90+ SOX9+ Cartilage-like Cells Initiate Spinal Ankylosis in Ankylosing Spondylitis
Sungsin Jo¹, Young Lim Lee ¹, Tae-Han Lee ¹, Ye-Soo Park ² and Tae-Hwan Kim ¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Department of Orthopedic Surgery, Hanyang University Medical Center, Guri Hospital,, Guri, Republic of Korea
Background/Purpose: Enthesitis is characterized by inflammation at the interface where tendon or ligament attaches to the bone and is a representative symptom of ankylosing spondylitis(AS).…
Abstract Number: 2455 • 2019 ACR/ARP Annual Meeting
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey
Ana-Maria Orbai¹, Birt Julie ², Elizabeth Holdsworth ³, Nicola Booth ⁴, Matthew M. Hufford ², Malatestinic William ², Aubrey Trevelin Sprabery ² and Anthony Reginato ⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Manchester, England, United Kingdom, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Division of Rheumatology, Providence VAMC, Associate Professor in Medicine, The Warren Alpert School of Medicine, Providence
Background/Purpose: Enthesitis, a characteristic clinical feature of psoriatic arthritis (PsA) [1], is a core outcome for PsA clinical trials. While enthesitis is considered important when…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Winnie Hua², Robert R. McLean², Peter Hur⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
Abstract Number: 1614 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Anwar Albasri¹, Justine Y. Ye², Cheryl F. Rosen³, Vinod Chandran², Dafna D Gladman⁴ and Lihi Eder⁵, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is one of the hallmarks of psoriatic arthritis (PsA) and may be the initial site of musculoskeletal inflammation. Enthesitis affects up to 50…
Abstract Number: 1632 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon
Alberto Batticciotto¹, Giada Prato², Marco Antivalle³, Maria Chiara Ditto⁴, Michele Agosti⁵, Enrico Cumbo², Rossella Talotta², Fabiola Atzeni⁶ and Piercarlo Sarzi-Puttini⁵, ¹SS Reumatologia Ospedale di Circolo - fondazione Macchi ASST Settelaghi, Varese, Italy, ²Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, ³Rheumatology, Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ⁴Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy, ⁵Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy, ⁶Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Enteropathic arthritis (EA) belongs to the spondyloarthritis (SpA) spectrum of diseases and occurs in patients affected by inflammatory bowel diseases (IBD). Several works demonstrated…
Abstract Number: 1657 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Philip Helliwell¹, Alice B Gottlieb², Atul A. Deodhar³, Wolf-Henning Boehncke⁴, Dennis McGonagle¹, Xie L. Xu⁵, Stephen Xu⁵, Yuhua Wang⁵, Elizabeth C Hsia^5,6, Chetan S Karyekar⁵ and Philip J. Mease⁷, ¹U of Leeds, Leeds, United Kingdom, ²NY Medical College, Metropolitan Hospital, NY, NY, ³Oregon Health & Science U, Portland, OR, ⁴U of Geneva, Geneva, Switzerland, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶U Penn School of Medicine, Phila, PA, ⁷Swedish Medical Center & U of Wash, Seattle, WA
Background/Purpose: In a Phase 2 study, Guselkumab (GUS) was shown to be safe & effective in pts w/active PsA w/meaningful improvements in enthesitis. To evaluate…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].